LifeMax certified for treating Netherton Syndrome with LM-030
Category: #health  | By Nikita Chaurasia  | Date: 2019-07-20 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

LifeMax certified for treating Netherton Syndrome with LM-030

LifeMax Laboratories Inc a subsidiary of LifeMax Healthcare International Corporation, recently announced that a Novartis licensed investigational therapy, LM-030, has been granted pediatric disease designation by the FDA. The therapy is now ready to enter critical clinical trials for the treatment of Netherton Syndrome, cite sources.

LifeMax Laboratories is a clinical stage biotech company focused on treating rare diseases with limited or no therapeutic options. 

For the record, Netherton Syndrome is an autosomal recessive disease with symptoms including bamboo hair congenital erythroderma & abnormality in the immune system. It can be lethal in pediatrics due to weakened skin barrier that leads to severe, hypothermia dehydration, sepsis, hypernatremia and gross weight loss.

Most patients with Netherton Syndrome also suffer with immune system related disorders such as asthma and food allergies. As a result of persistent cutaneous infection, chronic erythroderma, metabolic disorders & malnutrition, failure to thrive is common in childhood. Over time the acuteness of the skin abnormality can fluctuate in older patients.

Larry Hsu, Co-founder and CEO, LifeMax, was reportedly quoted saying that the company is elated on receiving rare pediatric disease designation for investigational LM-030, which has demonstrated safety & clinical efficacy in a Phase I as well as phase II study. He added that receiving the rare pediatric disease designation is a significant step in the development of LM-030 for treatment of Netherton Syndrome, which is a severe genetic disorder with neonate onset.

As per sources close to the matter, rare pediatric disease is defined by the Food and Drug Administration as a disease affecting less than 200,000 people in the United States and the most severe, life threatening indicator in pediatric patients.

If NDA new drug application for LM-030 is approved, the firm may be eligible for receiving a rare pediatric disease priority review voucher. The voucher can then be redeemed to obtain priority review for any subsequent BLA Biological License Application or NDA and can be sold or transferred.

Source credits: https://www.lifemaxhealthcare.com/july-18-2019

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

PM Liz Truss to launch comprehensive review of UK’s visa policy

PM Liz Truss to launch comprehensive review of UK’s visa policy

By Nikita Chaurasia

Newly appointed Prime Minister Liz Truss is considering doing a complete review of Britain's visa system, as the nation struggles with severe labor shortages in vital industries. Business leaders across the UK have reportedly praised the decision...

UAE: Entrepreneurs and investors can benefit from visa reforms

UAE: Entrepreneurs and investors can benefit from visa reforms

By Nikita Chaurasia

The visa and business reforms by the UAE will open new prospects for investors, entrepreneurs, IT specialists, job seekers, and tourists, according to credible sources. This will reportedly benefit the region’s economic growth. Business Link...

Flipkart introduces new tech and design upgrades ahead of holiday season

Flipkart introduces new tech and design upgrades ahead of holiday season

By Nikita Chaurasia

Flipkart, India's indigenous online marketplace, is reportedly offering customers an improved shopping experience on its widely popular app. To better serve various client groups that are exploring e-commerce during the holiday season, Flipkar...